Eduard Koifman

Dr. Eduard Koifman

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2024 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
EKEduard Koifman
Eduard Koifman
MAM. Armoni
M. Armoni
YGY. Gorelik
Y. Gorelik
AHA. Harbi
A. Harbi
YSY. Streltsin
Y. Streltsin
YMY. Mazor
Y. Mazor
Background: Rectal cancer is commonly treated by chemoradiation therapy, followed by the low anterior resection anal sphincter-preserving surgery, with a temporary protecting ileostomy. After reversal of the stoma a condition known as low anterior resection syndrome (LARS) can occur characterized by a combination of symptoms such as urgent bowel movements, lack of control over bowel movements, and difficulty fully emptying the bowels. These symptoms have a significant negative impact on the quality of life for individuals who have survived the cancer. Currently, there is limited available data regarding the presence, risk factors, and effects of treatment for these symptoms during long-term follow-up. Aims: To evaluate long term outcomes of low anterior resection surgery and its correlation to baseline anorectal manometry (ARM) parameters and physiotherapy with anorectal biofeedback (BF) treatment. Methods: One hundred fifteen patients (74 males, age 63 ± 11) who underwent low anterior resection surgery for rectal cancer were included in the study. Following surgery, patients were managed by surgical and oncologic team, with more symptomatic LARS patients referred for further evaluation and treatment by gastroenterologists. At follow up, patients were contacted and offered participation in a long term follow up by answering symptom severity and quality of life (QOL) questionnaires. Results: 80 (70%) patients agreed to participate in the long term follow up study (median 4 years from stoma reversal, range 1–8). Mean time from surgery to stoma closure was 6 ± 4 months. At long term follow up, mean LARS score was 30 (SD 11), with 55 (69%) patients classified as major LARS (score > 30). Presence of major LARS was associated with longer time from surgery to stoma reversal (6.8 vs. 4.8 months; p = 0.03) and with adjuvant chemotherapy (38% vs. 8%; p = 0.01). Patients initially referred for ARM and BF were more likely to suffer from major LARS at long term follow up (64% vs. 16%, p < 0.001). In the subgroup of patients who underwent perioperative ARM (n = 36), higher maximal squeeze pressure, higher maximal incremental squeeze pressure and higher rectal pressure on push were all associated with better long-term outcomes of QOL parameters (p < 0.05 for all). 21(54%) of patients referred to ARM were treated with BF, but long term outcomes for these patients were not different from those who did not perform BF. Conclusions: A significant number of patients continue to experience severe symptoms and a decline in their quality of life even 4 years after undergoing low anterior resection surgery. Prolonged time until stoma reversal and adjuvant chemotherapy emerged as the primary risk factors for a negative prognosis. It is important to note that referring patients for anorectal physiology testing alone tended to predict poorer long-term outcomes, indicating the presence of selection bias. However, certain measurable manometric parameters could potentially aid in identifying patients who are at a higher risk of experiencing unfavorable functional outcomes. There is a critical need to enhance current treatment options for this patient group.

23 August 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
EKEduard Koifman
Eduard Koifman
MKMeytal Krasnopolsky
Meytal Krasnopolsky
IGItai Ghersin
Itai Ghersin
MWMatti Waterman
Matti Waterman
Background: Osteoporosis prevalence is increased in Crohn’s disease (CD). Its pathogenesis in these patients is incompletely understood. Objectives: To identify factors associated with decreased bone mineral density (BMD) status in CD patients on a time-line course. Methods: A retrospective study was performed that followed CD patients who underwent at least two bone mineral density scans (DEXAs). Follow-up began one year prior to the first DEXA test and lasted at least one year after a second test. Possible correlations between baseline and follow-up variables and changes in BMD status were examined. Change in BMD was defined as a transition from one bone density category to another (normal vs. osteopenia vs. osteoporosis). Binary variables were assessed using the Cochrane–Armitage test. Categorical variables were assessed using the chi-squared test. A multivariate analysis was performed. Results: The study included 141 patients. At baseline, 33 patients (23.4%) had normal BMD, 75 (53.2%) had osteopenia, and 33 (23.4%) had osteoporosis. Patients with low BMD had a lower baseline BMI compared to those with normal BMD (p < 0.0001). After a median follow-up of 48 months (IQR 29–71), BMD status worsened in 19 (13.5%) patients, whereas in 95 (67.3%) and 27 (19.1%) patients, BMD remained unchanged or improved, respectively. On the multivariate analysis, elevated median CRP throughout follow-up (OR = 0.8, 95% CI: 0.68–0.93) and low baseline BMI (OR = 0.9, 95% CI: 0.83–0.98) were associated with a lack of BMD status improvement. Conclusions: Persistently elevated CRP and low BMI are associated with a lack of improvement in BMD. These findings underscore the importance of effective inflammation control and nutritional support to maintain and improve bone health.

1 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
IGItai Ghersin
Itai Ghersin
MFMaya Fischman
Maya Fischman
GCGiacomo Calini
Giacomo Calini
EKEduard Koifman
Eduard Koifman
VCValerio Celentano
Valerio Celentano
AHAilsa Hart
Ailsa Hart
Background/Objectives: Anti-tumour necrosis factor (anti-TNF) medications were historically commonly prescribed as the first-line biologic treatment for chronic inflammatory pouch conditions. However, their use in these conditions is mainly based on retrospective studies of relatively small numbers of patients with short follow up periods. We aimed to describe the long-term outcomes of first-line anti-TNF therapy in a large, multi-centre, multi-national patient cohort with chronic inflammatory pouch conditions. Methods: This was an observational, retrospective, multi-centre, multi-national study. We included patients with chronic inflammatory pouch conditions initially treated with anti-TNF drugs infliximab (IFX) or adalimumab (ADA), who had a follow up of at least 1 year. The primary outcome was anti-TNF treatment persistence, defined as continuation of anti-TNF throughout the study period. The secondary outcome was pouch failure, defined by the need for a defunctioning ileostomy or pouch excision. Results: We recruited 98 patients with chronic inflammatory pouch conditions initially treated with anti-TNF medications—63 (64.3%) treated with IFX and 35 (35.7%) treated with ADA. Average follow up length was 94.2 months (±54.5). At the end of the study period only 22/98 (22.4%) patients were still on anti-TNF treatment. In those in whom the first-line anti-TNF was discontinued, the median time to discontinuation was 12.2 months (range 5.1–26.9 months). The most common cause for anti-TNF discontinuation was lack of efficacy despite adequate serum drug levels and absence of anti-drug antibody formation (30 patients, 30.6%). Loss of response due to anti-drug antibody formation was the cause for discontinuation in 18 patients (18.4%), while 12 patients (12.2%) stopped treatment because of adverse events or safety concerns. Out of the 76 patients discontinuing anti-TNF treatment, 34 (34.7% of the cohort) developed pouch failure, and 42 (42.8% of the cohort) are currently treated with a different medical therapy. Conclusions: First-line anti-TNF therapy for chronic pouch inflammatory conditions is associated with low long-term persistence rates. This is due to a combination of lack of efficacy and adverse events. A significant percentage of patients initially treated with anti-TNF therapy develop pouch failure.

18 August 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
EKEduard Koifman
Eduard Koifman
ICInna Spector Cohen
Inna Spector Cohen
RLRebeca Lopez-Alonso
Rebeca Lopez-Alonso
DHDana Ben Hur
Dana Ben Hur
AIAnat Ilivitzki
Anat Ilivitzki
MWMatti Waterman
Matti Waterman
Fibrofatty proliferation of mesenteric fat is a common finding on magnetic resonance enterography (MRE) in Crohn’s disease (CD) patients. Mesenteric fat may play a role in inflammation, fibrosis, and stricture formation, but its prognostic value in predicting complications remains unclear. To assess the association between mesenteric fat proliferation on MRE and the risk of hospital admissions and bowel surgery in CD patients. In this retrospective single-center study, CD patients with available MRE data were followed for CD exacerbation-related hospitalizations or abdominal surgeries. An expert radiologist reviewed MRE for intestinal wall thickening, stricture, abscess formation, fibrofatty proliferation, and fat edema. Kaplan-Meier and Cox proportional hazards regression models were used to analyze associations between mesenteric fat and outcomes, adjusting for clinical and imaging characteristics. Among 175 CD patients mesenteric fat proliferation and edema were noted in 52 (29.7%) and 15 (8.9%) patients, respectively. Other findings included wall thickening (46.9% mild, 29.1% moderate, 7.4% severe), stricture (14.3%), abscess (5.7%), and fistula (6.9%). During a mean follow-up of 95.2 months, 93 (51.3%) patients were hospitalized for CD-related reasons, and 47 (26.9%) underwent CD-related abdominal surgery. Mesenteric fat proliferation was strongly associated with hospitalizations and surgery (p < 0.0001 for both). Multivariable analysis confirmed these associations with adjusted hazard ratios (aHR) of 3.45 (95%CI 1.66–7.19) 3.74 (95%CI) for surgery and 1.92 (95%CI 1.16–3.15) 2.03 (95%CI) for hospitalizations. Fat edema was linked to surgery and hospitalization but lost significance in multivariable analysis. Mesenteric fat proliferation on MRE is independently associated with increased risk of hospitalizations and surgery in CD patients.

30 June 2023 in Research Square
Verified
Preprint
Open access
PDF file
EKEduard Koifman
Eduard Koifman
MAMor Armoni
Mor Armoni
YGYuri Gorelik
Yuri Gorelik
AHAssaf Harbi
Assaf Harbi
YSYulia Streltsin
Yulia Streltsin
YMYoav Mazor
Yoav Mazor
Background Rectal cancer is commonly treated by chemo-radiation therapy, followed by anal sphincter-preserving surgery, with a temporary protecting ileostomy. After the reversal of the stoma, a condition known as low anterior resection syndrome (LARS) can occur, characterized by a combination of symptoms such as urgent bowel movements, lack of control over bowel movements, and difficulty fully emptying the bowels. These symptoms have a significant negative impact on the quality of life for individuals who have survived cancer. Currently, there is limited available data regarding the presence, risk factors, and effects of treatment for these symptoms during long-term follow-up.Aims: To evaluate long term outcomes of sphincter-preserving surgery and its correlation to baseline anorectal manometry (ARM) parameters and physiotherapy with anorectal biofeedback (BF) treatment. Methods 115 patients (74 males, age 63 ± 11) who underwent sphincter preserving surgery for rectal cancer were included in the study. Following surgery, patients were managed by surgical and oncologic team, with more symptomatic LARS patients referred for further evaluation and treatment by gastroenterologists. At follow up, a cross sectional observational study was performed. Patients were contacted and offered participation in a long term follow up by answering symptom severity and quality of life (QOL) questionnaires. Results 80 (70%) patients agreed to participate in the long term follow up study (median 4 years from stoma reversal, range 1–8). Mean time from surgery to stoma closure was 6 ± 4 months. At long term follow up, mean LARS score was 30 (SD 11), with 55 (69%) patients classified as severe LARS (score > 30). Presence of severe LARS was associated with longer time from surgery to stoma reversal (6.8 vs. 4.8 months, p = 0.03). Patients initially referred for ARM and BF were more likely to suffer from severe LARS at long term follow up (64% vs. 16%, p < 0.001). In the subgroup of patients who underwent perioperative ARM (n = 36), higher maximal squeeze pressure, higher maximal incremental squeeze pressure and higher rectal pressure on push were all associated with better long-term outcomes of QOL parameters as measured by questionnaires (p < 0.05 for all). 19 (53%) of these patients were treated with BF, but long term outcomes for these patients were not different from those who did not perform BF. Conclusions A significant number of patients continue to experience severe symptoms and a decline in their quality of life even four years after undergoing sphincter-preserving surgery. Prolonged time until stoma reversal emerged as the primary risk factor for a negative prognosis. It is important to note that referring patients for anorectal physiology testing alone tended to predict poorer long-term outcomes, indicating the presence of selection bias. However, certain measurable manometric parameters could potentially aid in identifying patients who are at a higher risk of experiencing unfavorable functional outcomes. There is a critical need to enhance current treatment options for this patient group, which may involve implementing a more comprehensive anorectal bowel function protocol and considering sacral neuromodulation as potential interventions.